Neuromuscular Relaxants Flashcards

1
Q

Describe the mechanisms by which skeletal muscle nicotinic receptor activation stimulates skeletal muscle contraction, including the agonists, receptors, and postsynaptic mechanisms that initiate contraction.

A
  1. pre-synaptic neuron releases ACh into the synaptic cleft
  2. muscle nicotinic receptors (Nm) act as binding sites for the ACh
  3. activation of Nm receptors opens up Na+ channels for depolarization
  4. sufficient Na+ influx causes depolarization to travel down the T-Tubules (requires enough Na channels in the resting state)
  5. calcium influx leads to muscle contraction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Compare the 2 distinct mechanisms by which depolarizing and non-depolarizing neuromuscular blockers mediate their effects on the motor end plate.

A

NON-DEPOLARIZING = competitive antagonists

  • block the nicotinic ACh receptors (curare crayons)
  • overcome by excess ACh via tetanic stimulation or cholinesterase inhibitors (neostigmine store owner yells at curare kid)
  • at higher concentrations, nicotinic channel pore is blocked => not as sensitive to excess ACh

DEPOLARIZING = agonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Compare the pharmacokinetics of the 2 classes of neuromuscular blockers.

A

NON-DEPOLARIZING
- competitive binding of nicotinic receptors prevents membrane depolarization and end-plate potential
- rapid distribution
- t1/2 depends on route of elimination (kidney > liver > plasma cholinesterase (metabolic))
=> avoid drugs metabolized by the liver if the patient has liver failure
=> avoid drugs metabolized by the kidney if the patient has renal failure
- biological half-life is longer than therapeutic effect due to receptor reserve

DEPOLARIZING

  • more rapid onset that ND
  • rapidly metabolized by plasma cholinesterases
  • action terminated by diffusion out of the synapse
  • genetic variations in cholinesterase can prolong drug effect
  • clinical manifestation: arm => neck => leg => diaphragm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe how cholinesterase inhibition affects the paralysis produced by each type of neuromuscular blocker.

A

NON-DEPOLARIZING
- overcome paralysis when given ChE inhibitors

DEPOLARIZING

  • Phase I - exacerbation
  • Phase II - overcome paralysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

List the mechanisms by which the action of both classes of neuromuscular blockers are terminated.

A

ND
- AChE inhibitors

D

  • Phase I - diffusion
  • Phase II - AChE inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the prominent side effects of each class of skeletal muscle relaxants.

A

NON-DEPOLARIZING

  • non-analgesic
  • apnea
  • drug interactions with inhalant anesthetics (enhanced effect)

DEPOLARIZING

  • non-analgesic
  • apnea
  • muscle pain
  • stimulation of nicotinic autonomic and muscarinic cardiac receptors (arrhythmia, HTN, bradycardia)
  • hyperkalemia due to K+ release from motor end plate
  • malignant hyperthermia
  • drug interactions with local anesthetics (enhanced effect)
  • drug interactions with cholinesterase inhibitors (enhances Phase I)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

List the antidote for either class of neuromuscular blockers.

A

NON-DEPOLARIZING

  • cholinesterase inhibitors (neostigmine store owner yells at curare kid)
  • muscarinic blockers to minimize cholinesterase inhibitor action on the muscarinic receptors (glycopyrrolate)

DEPOLARIZING
- Phase I = none; rapidly hydrolyzed by plasma cholinesterase
=> atropine for bradycardia due to muscarinic effects
- Phase II = cholinesterase inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the characteristics of phase I and phase II block with depolarizing neuromuscular blockers and describe why phase II should be avoided.

A
  • Phase I - succinylcholine binds to the nicotinic ACh receptor and causes motor end plate depolarization => transient contraction => succinylcholine is NOT degraded by acetylcholinesterase (requires plasma cholinesterase) => continuous depolarization of the AChR => not enough time for Na+ channels to return to resting => inactivated Na+ channels => no further AP => flaccid paralysis
    => tx with ChE inhibitors will augment blockade
  • Phase II - succinylcholine enters the pore => membrane becomes repolarized, but receptor is desensitized;
    => acts like non-depolarizing muscle block
    => overcome by treatment with cholinesterase inhibitors or tetanic stimulation
    => but must confirm that Phase I is over b/c ChE inhibitors will augment muscle block when in Phase I
    => monitor patient for muscle action
    => avoid this phase by co-treatment with ChE inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the characteristics of pancuronium, rocuronium, and vecuronium. Why is one agent preferable over another in long term ventilation, intubation of a healthy patient, or patient with renal failure for a short procedure or a moderate lengthy orthopedic surgery.

A
  1. long-term ventilation - roc
  2. intubation of a health patient - roc
  3. patient with renal failure for a short procedure - roc, mivac
  4. longer orthopedic surgery = pan
  • avoid drugs metabolized by the liver if the patient has liver failure
  • avoid drugs metabolized by the kidney if the patient has renal failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the mechanisms by which baclofen and benzodiazepines alter somatic motor neuron excitation.

A
  • reduce activity of Ia fibers that excite the primary motor neuron
  • enhance activity of the internuncial inhibitory neuron
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

List the major side effects of baclofen and benzodiazepines and discuss how the route of delivery can reduce side effects.

A

major SE = drowsiness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

List the following for Tizanidine.

  • MOA
  • SE
  • use
A

TIZANIDINE

  • MOA: alpha-2 agonist (promotes inhibition of sympathetic activity in spinal cord)
  • SE: drowsiness, hypotension
  • use: MS and spinal spasticity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Define muscle twitch, clonus, and tetany.

A

twitch - action potential-dependent increase in intracellular calcium followed by reduction (sequestered in SR)

clonus - increased frequency of stimulation leads to incomplete relaxation;

tetany - no reduction in calcium between stimuli => muscle contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe how receptor reserve relates to the pharmacodynamics of curare compounds (non-depolarizing competitive antagonists).

A
  • high receptor occupancy is required before an effect is observed
  • % receptors occupied to inhibit contraction is proportional to (~) receptor reserve
  • ex: 75% receptor occupancy is required before seeing any detriment in function, while 100% is required for full muscle relaxation
  • biological half-life of curare compounds is longer than their therapeutic effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe how receptor reserve creates a characteristic onset of drug effect for curare compounds (non-depolarizing competitive antagonists).

A
  • different muscle beds have different receptor reserve and thus require different plasma concentration of curare to inhibit contraction
    => respiratory muscles > larger limb and trunk > fine muscles

EFFECTS
extraocular => hands and feet => head and neck => abdomen and extremities => diaphragm and respiratory muscles

This is because the lower the receptor reserve, the quicker therapeutic effects are reached (muscle weakness and paralysis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the clinical uses for non-depolarizing and depolarizing neuromuscular relaxants?

A

ND

  • muscle relaxation for surgeries
  • intubation (rocuronium, mivacurium)
  • ventilation

D

  • endotracheal intubation
  • controlling convulsions during EST
17
Q

What are the contraindications for depolarizing muscle blockers?

A
  • hx of familial malignant hyperthermia
18
Q

List the following for baclofen:

  • MOA
  • clinical use
  • side effects
A
  • MOA: GABAb agonist => GABA binds to GABAb receptor on pre-synaptic nerve terminal => reduces calcium influx => inhibits excitatory transmitter release
  • clinical use: spinal spasticity
  • side effects: drowsiness
19
Q

List the following for benzodiazepams (diazepam, clonazepam).

  • MOA
  • clinical use
  • side effects
A
  • MOA: enhances GABA effect by binding to GABAa on the post-synaptic neuron => Chlorine influx => hyperpolarizes the neuron => less likely to cause AP
  • clinical use: spinal spasticity and MS
  • side effects: sedation and drowsiness
20
Q

List the following for dantrolene:

  • MOA
  • SE
  • use
A
  • MOA: blocks intracellular calcium release from CA (block ryanodine receptor)
  • SE: sedation, muscle weakness
  • use: spasticity and malignant hyperthermia (characterized by prolonged calcium release)
21
Q

List the following for pancuronium:

  • duration
  • MOA
  • elimination route
  • use
A
  • duration: 30-60 min
  • MOA: non-depolarizing competitive antagonist of nicotinic ACh receptors
  • RoE: renal
  • use: surgical anesthesia, abdominal wall relaxation, and orthopedic procedures
22
Q

List the following for D-tubocurarine:

  • duration
  • MOA
  • elimination route
  • use
A
  • duration: >60 min.
  • MOA: non-depolarizing competitive antagonist of nicotinic ACh receptors
  • RoE: liver clearance and renal elimination
  • use: prototype; lethal injection
23
Q

List the following for rocuronium:

  • duration
  • MOA
  • elimination route
  • use
A
  • duration: 25 min.
  • MOA: non-depolarizing competitive antagonist of nicotinic ACh receptors
  • RoE: liver
  • use: intubation, muscle relaxation during surgery, ventilation
24
Q

List the following for mivacuronium:

  • duration
  • MOA
  • elimination route
  • use
A
  • duration: 15-20 min.
  • MOA: non-depolarizing competitive antagonist of nicotinic ACh receptors
  • RoE: metabolic plasma cholinesterases
  • use: intubation, muscle relaxation during surgery, ventilation with renal failure patients
25
Q

List the following for vecuronium:

  • duration
  • MOA
  • elimination route
  • use
A
  • duration: 30-45 min.
  • MOA: non-depolarizing competitive antagonist nicotinic ACh receptors
  • RoE: liver clearance and renal elimination
  • use: surgical anesthesia, abdominal muscle relaxation, orthopedic surgeries